Published in Am J Pathol on July 01, 1983
BN 52021 (a platelet activating factor-receptor antagonist) decreases alveolar macrophage-mediated lung injury in experimental extrinsic allergic alveolitis. Mediators Inflamm (1998) 1.39
Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs. Br J Pharmacol (1990) 1.14
Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol (1989) 1.06
PAF-induced bronchial hyperresponsiveness in the rabbit: contribution of platelets and airway smooth muscle. Br J Pharmacol (1990) 0.97
Effect of platelet agonists on airway reactivity and intrathoracic platelet accumulation. Br J Pharmacol (1987) 0.92
Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit. Am J Pathol (1985) 0.90
Lung injury mediated by antibodies to endothelium. II. Study of the effect of repeated antigen-antibody interactions in rabbits tolerant to heterologous antibody. Am J Pathol (1987) 0.86
Mechanism of action of platelet activating factor in the pulmonary circulation: an investigation using a novel isotopic system in rabbit isolated lung. Br J Pharmacol (1991) 0.84
Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects. Br J Clin Pharmacol (1988) 0.84
The involvement of platelet activating factor in endotoxin-induced pulmonary platelet recruitment in the guinea-pig. Br J Pharmacol (1987) 0.81
Phospholipase A2-induced pathophysiologic changes in the guinea pig lung. Am J Pathol (1990) 0.78
Determination of the platelet activating factor in silicotic patients and its effect on fibroblasts. Environ Health Prev Med (2001) 0.75
Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med (1972) 5.38
Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem (1979) 4.31
[Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine]. C R Seances Acad Sci D (1979) 2.53
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol (1979) 2.31
Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). J Immunol (1981) 2.19
Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest (1982) 2.14
Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol (1979) 2.10
Preparation, sensitivity, and specificity of Limulus lysate for endotoxin assay. Appl Microbiol (1973) 2.09
Structural analysis of purified platelet-activating factor by lipases. Nature (1977) 2.09
The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol (1979) 2.02
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol (1980) 1.77
Complement fragments, alveolar macrophages, and alveolitis. Am J Pathol (1979) 1.69
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology (1981) 1.62
Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine. J Biol Chem (1980) 1.61
Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents. Biochem Biophys Res Commun (1980) 1.50
Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest (1980) 1.50
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
Activation and desensitization of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. I. Characteristics of the secretory response. J Exp Med (1976) 1.48
Experimental immune complex disease of the lung. The pathogenesis of a laboratory model resembling certain human interstitial lung diseases. J Exp Med (1974) 1.48
A differential effect of C5a and C5a des Arg in the induction of pulmonary inflammation. Am J Pathol (1980) 1.46
Lung inflammation induced by complement-derived chemotactic fragments in the alveolus. Lab Invest (1980) 1.38
Absence of inflammatory lung injury in rabbits challenged intravascularly with complement-derived chemotactic factors. Am Rev Respir Dis (1982) 1.31
Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int Arch Allergy Appl Immunol (1981) 1.27
Induction of leukocytic infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine. Lab Invest (1982) 1.26
Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). J Immunol (1982) 1.15
IgE-induced release of a platelet-activating factor from rabbit lung. J Immunol (1975) 1.13
Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol (1980) 1.12
Immune complex injury of the lung. Symposium held at the 74th annual meeting of the American Thoracic Society, Las Vegas, Nevada, May 1979. Am Rev Respir Dis (1981) 1.08
Induction of acute inflammatory reactions in lung following intrapulmonary instillation of preformed chemotactic peptides and purified complement components. Chest (1979) 1.05
Experimental anti-alveolar basement membrane antibody-mediated pneumonitis. I. The role of increased permeability of the alveolar capillary wall induced by oxygen. J Immunol (1981) 1.00
Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness: role of basophil-derived PAF in immune complex deposition. J Immunol (1982) 0.99
Chemotactic activity of C5ades Arg: evidence of a requirement for an anionic peptide 'helper factor' and inhibition by a cationic protein in serum from patients with systemic lupus erythematosus. Mol Immunol (1980) 0.97
Release of platelet-activating factor by peritoneal and alveolar macrophages. Monogr Allergy (1979) 0.88
Mediators of immune complex-induced aggregation of polymorphonuclear neutrophils. I. C5a anaphylatoxin, neutrophil cationic proteins and their cleavage fragments. Int Arch Allergy Appl Immunol (1980) 0.88
Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int (2007) 2.75
The release of platelet-activating factor from human endothelial cells in culture. J Immunol (1983) 2.41
Pyrogen retention by highly permeable synthetic membranes during in vitro dialysis. Artif Organs (2001) 2.01
Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J Histochem Cytochem (1994) 1.72
The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med (1996) 1.72
Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev (2000) 1.70
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology (1981) 1.62
Human liver stem cell-derived microvesicles accelerate hepatic regeneration in hepatectomized rats. J Cell Mol Med (2009) 1.58
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest (1986) 1.57
Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol (2001) 1.57
Antibody-induced redistribution of Heymann antigen on the surface of cultured glomerular visceral epithelial cells: possible role in the pathogenesis of Heymann glomerulonephritis. J Immunol (1985) 1.52
Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. J Biol Chem (1988) 1.52
The molecular action of tumor necrosis factor-alpha. Eur J Biochem (1991) 1.52
Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis (1990) 1.50
HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest (1998) 1.49
Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol (1987) 1.46
Online clearance measurement in high-efficiency hemodiafiltration. Kidney Int (2007) 1.42
Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int Arch Allergy Appl Immunol (1981) 1.27
Glomerulonephritis induced in the rabbit by antiendothelial antibodies. J Clin Invest (1987) 1.25
Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology (1977) 1.25
Maternal vascular prostacyclin activity in pre-eclampsia. Lancet (1980) 1.24
Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. Lab Invest (1984) 1.24
Formation of immune deposits and disease. Lab Invest (1986) 1.20
Disseminated immune deposits in lupus erythematosus. Arthritis Rheum (1977) 1.18
Role of soluble mediators in angiogenesis. Eur J Cancer (1996) 1.17
Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int (2001) 1.17
Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med (1994) 1.17
Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost (2007) 1.16
Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J Immunol (1985) 1.16
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol (2000) 1.14
Alternative pathway activation of complement by cultured human proximal tubular epithelial cells. Kidney Int (1994) 1.12
Detection of two forms of GP330. Their role in Heymann nephritis. Am J Pathol (1993) 1.11
Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol (1998) 1.11
Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J Exp Med (1993) 1.11
C reactive protein in patients with chronic renal diseases. Ren Fail (2001) 1.10
Potential role of platelet-activating factor in renal pathophysiology. Kidney Int (1986) 1.09
Development of inflammatory angiogenesis by local stimulation of Fas in vivo. J Exp Med (1997) 1.09
The epidemiology of cardiac surgery-associated acute kidney injury. Int J Artif Organs (2008) 1.08
Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol (1981) 1.08
Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol (1999) 1.08
Endothelial progenitor cell-derived microvesicles improve neovascularization in a murine model of hindlimb ischemia. Int J Immunopathol Pharmacol (2012) 1.07
Synthesis and release of platelet-activating factor is inhibited by plasma alpha 1-proteinase inhibitor or alpha 1-antichymotrypsin and is stimulated by proteinases. J Exp Med (1988) 1.07
Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol Dial Transplant (1997) 1.06
Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int (1998) 1.05
Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells. J Immunol (1983) 1.04
Expression and modulation of surface antigens in cultured rat glomerular visceral epithelial cells. J Histochem Cytochem (1989) 1.04
Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-alpha. Am J Pathol (1997) 1.04
Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res (1999) 1.03
Murine monoclonal antibodies as probes for the phenotypical, functional, and molecular analysis of a discrete peripheral blood lymphocyte population exerting natural killer activity in vitro. Hum Immunol (1985) 1.03
Localization of neutrophil cationic proteins and loss of anionic charges in glomeruli of patients with systemic lupus erythematosus glomerulonephritis. Clin Immunol Immunopathol (1982) 1.03
Serological screening for coeliac disease in vitiligo and alopecia areata. Br J Dermatol (1997) 1.03
Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with alpha3 chain of type IV collagen. Kidney Int (1998) 1.03
Mortality risk for patients receiving hemodiafiltration versus hemodialysis. Kidney Int (2006) 1.03
Acute renal failure secondary to interstitial lupus nephritis. Arch Intern Med (1978) 1.02
Pathogenesis of passive Heymann glomerulonephritis: chlorpromazine inhibits antibody-mediated redistribution of cell surface antigens and prevents development of the disease. J Immunol (1986) 1.02
Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. J Exp Med (1996) 1.02
Release of platelet-activating factor from ischemic-reperfused rabbit heart. Am J Physiol (1989) 1.01
Distinct pathogenic effects of group B coxsackieviruses on human glomerular and tubular kidney cells. J Virol (1997) 1.01
Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol (2006) 1.01
The role of platelet-activating factor in inflammation. Clin Immunol Immunopathol (1990) 0.99
Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia (2007) 0.99
The pathogenesis of pericardial, pleural, and peritoneal effusions in rabbits with serum sickness. Lab Invest (1977) 0.99
In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis. Arterioscler Thromb Vasc Biol (1995) 0.99
Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes. Proc Natl Acad Sci U S A (1986) 0.99
Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness: role of basophil-derived PAF in immune complex deposition. J Immunol (1982) 0.99
Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis. Kidney Int (1995) 0.98
CD40-CD154 interaction in experimental and human disease (review). Int J Mol Med (1999) 0.98
Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol (1990) 0.98
Thymectomy and renal homotransplantation. Clin Exp Immunol (1970) 0.98
Tumor-derived microvesicles and the cancer microenvironment. Curr Mol Med (2013) 0.98
Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol (1990) 0.97
Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant (2006) 0.97
Net histocompatibility ratios (NHR) for clinical transplantation. Transplant Proc (1971) 0.97
Tumor necrosis factor induces contraction of mesangial cells and alters their cytoskeletons. Kidney Int (1990) 0.96
Interaction of antibodies with renal cell surface antigens. Kidney Int (1989) 0.96